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1. Study Synopsis 
Knee osteoarthritis (OA) is a major cause of chronic pain and a leading cause of functional 
disability in the elderly 1. Total knee arthroplasty (TKA) is considered an effective treatment in 
end-stage knee OA 2, but the indications have broadened to include younger patients 3, 4 and 
patients with less severe symptoms 5. This highlights the demand for consensus on the indication 
for TKA in knee OA and requires the development of high quality evidence for the treatment 
options in knee OA. This randomized, controlled trial aims at investigating whether TKA 
provides further improvement in addition to a 12-week non-surgical treatment program 
(MEDIC; neuromuscular exercise, patient education, weight loss (if needed), insoles and 
medicine) in patients eligible for a TKA (Figure 1).  
Patients fulfilling the eligibility criteria, but refusing to participate in the randomization, were 
offered to participate in an observational cohort, were they were able to choose which of the two 
treatment options they wanted. They followed the same intervention, follow-up schedule and 
study endpoints as patients in the randomized controlled trial, but were analyzed separately. 
2. Study Objectives and Outcomes 
A study protocol elaborating the methods used in this study has been published 6.  All outcomes 
were obtained from all participants at baseline and all follow-ups (3months, 6months and 
12months; Figure 1). The 12month follow-up is expected to be finalized in February 2015.  
2.1. Primary Objective and Outcome 
The primary objective is to compare the change from baseline to the 1 year follow-up (including 
all follow-ups) between patients randomized to the MEDIC-treatment or TKA + the MEDIC-
treatment in the average score of four of the five subscales from the Knee Injury and 
Osteoarthritis Outcome Score (KOOS4) covering pain, symptoms, activities of daily living 
(ADL), and knee-related quality of life (QOL).  
An overall KOOS-score can be used as primary endpoint in an RCT, if defined a priori 7. 
However, the purpose of an overall score (KOOS4) as the primary endpoint is to avoid issues 
with multiplicity. Since an overall score has not been subjected to psychometric validation the 
individual KOOS subscales must be analyzed as secondary outcomes to enable clinical 
interpretation of the contributions of the individual subscales to the overall KOOS4 score 
7. 
The reason for not including the KOOS subscale Sports & recreation function (Sport/Rec) in the 
primary endpoint KOOS4 was that it was expected that a large proportion of the participants in 
this study would not perform the activities assessed in this subscales (running, jumping, 
squatting, kneeling and pivoting). This could potentially affect the content validity, which is 
why it was excluded from the aggregated primary outcome.  
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Each item in KOOS is scored from 0-4 on a Likert scale. Subscale scores are given separately 
(see www.koos.nu for user’s guide and scoring) ranging from 0 [worst] to 100 [best]. KOOS has 
previously been validated for patients eligible for TKA 8, 9. Each subscale of the primary 
outcome of this study, KOOS4, will be calculated according to the instructions in the user’s 
guide. After that an average of the four subscales will be calculated giving each subscale equally 
large impact on the KOOS4 score using this formula: 
 KOOS4 = (KOOS Pain + KOOS Symptoms + KOOS ADL + KOOS QOL)/4 
2.2. Secondary Objectives and Outcomes 
The secondary objectives are to compare change from baseline to the 1 year follow-up 
(including all follow-ups) between groups in a range of outcomes. These outcomes will only be 
supportive, explanatory and/or hypothesis generating, which is why multiplicity is not 
considered to be a problem10.  
The outcomes are (arranged hierarchically according to their importance): 
1) The five subscales of KOOS: 
a. Symptoms 
b. Pain 
c. ADL 
d. Sport/Rec 
e. QOL 
2) Functional performance 
a. Time from the Timed Up and Go 12 
b. Time from the 20-meter walk test 13 
3) The descriptive system (EQ-5D Index) and the EQ VAS (0-100) from the Euro-Quality-
of-Life – 5 Dimensional form (EQ-5D-3L) 11. 
4) Weight change in percent measured without shoes at the same time of day and on the 
same scale (seca 813, seca gmbh & co. kg., Hamburg, Germany) 
5) Usage of pain killers during the last week (yes/no), number of weekly paracetamols (1g) 
and ibuprofen (400mg) and other NSAIDs. 
6) Adverse events (AE) and seriously adverse events (SAE) will be registered in three ways 
and divided into index knee or sites other than index knee. The project physiotherapist 
will record any adverse events that the participant experiences or tells them about. For 
the participants allocated to, or crossing over to, TKA, a project worker will look 
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through hospital records to register if any pre-defined perioperative and postoperative 
adverse events occurred. At all follow-ups, the assessor will use open-probe questioning 
to assess adverse events in all participants (Table 1). 
2.3. Exploratory Objectives 
The exploratory objectives are to compare change from baseline to the 1 year follow-up 
(including all follow-ups) between groups in a range of outcomes. These outcomes will only be 
exploratory and/or hypothesis generating, which is why multiplicity is not considered to be a 
problem 10.  
The outcomes are: 
1) Pain intensities on a 100 mm VAS with terminal descriptors of ‘no pain’ and ‘worst pain 
possible’ in the following situations: at rest, at night, after 50 m of walking, after 30 min. 
of walking, after exercise/physical activity, during preferred physical activity, and worst 
pain and least pain in the previous 24 hours. 
2) Number of sites with pain in the previous 24 hours shaded on a region-divided body 
chart 
3) Pain location and type assessed using the reliable interviewer-administered questionnaire 
Knee Pain Map 14. 
4) Maximum isometric muscle strength (converted to Nm using the length of the lower leg) 
measured bilaterally in knee flexion and knee extension in a make test using a handheld 
dynamometer (Powertrack II
TM
 Commander from JTech Medical Industries, Salt Lake 
City, Utah, USA) 
5) Pressure pain thresholds measured bilaterally using a handheld algometer (Algometer 
Type II, Somedic AB, Hoerby, Sweden)) at five sites at the knee and the m. tibialis 
anterior muscle 15.  
6) Self-efficacy in improving pain, function and QOL in various situations using a 100 mm 
VAS with terminal descriptors of ‘very unsure’ and ‘very sure’. 
Additionally, an analysis will be conducted to investigate if treatment compliance (se section 
2.5.) is associated with the change in KOOS4. 
 
Based on recent studies in similar patient populations 16, 17, an exploratory analysis applying a 
15% difference in change in KOOS4 between groups from baseline to the 1 year follow-up as the 
Minimal Important Change (MIC; see section 2.6.) will be conducted. 
 
An analysis of Number Needed to Treat (NNT) will be performed. NNT estimates the number 
of people who would need to go through the TKA + MEDIC-treatment for one person to have a 
MIC (15%) in KOOS4 from baseline to the 12 month follow-up compared to the MEDIC-
treatment alone. 
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Furthermore changes in the following exploratory outcomes from baseline to 3 months will be 
compared between groups to investigate the effects on pain sensitization: 1), 2), 3), and 5).  
The test setup for muscle strength and pressure pain thresholds will be assessed in a study of 
test-retest reliability of 20 knee OA patients.  
Further exploratory objectives may be added later on. 
2.4. Economic Evaluation 
The EQ-5D will be applied in a health economic evaluation11. 
 
Figure 1: Flow chart 
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2.5. Descriptive Outcomes 
Baseline characteristics will be presented in a table (Table 2). 
Furthermore, the following treatment-related variables will be presented descriptively:  
1) Compliance with exercise will be recorded by the physiotherapist during the 12 weeks. 
Compliance is assessed as the total number of exercise sessions completed out of the 
total 24 sessions (two sessions a week over twelve weeks).  Good compliance is defined 
as participation in 75 % or more of the exercise sessions, moderate compliance as 
participation in 50-74 % of the sessions and poor compliance as participation in less than 
50 % of the sessions. 
2) Compliance with insoles, patient education and dietary advice will be assessed at each 
follow-up, using a five-point scale assessing the adherence to the treatment (never, every 
month, every week, every day, all the time).  
3) Satisfication with the treatment effect will be registered at each follow-up on a five-point 
Likert scale (very dissatisfied, dissatisfied, neither satisfied nor dissatisfied, satisfied, 
very satisfied). Surgery during the 12 month follow-up period will also be registered 
(Table 3).  
2.6. Specification of endpoints 
2.6.1. Primary Endpoint 
The primary outcome (KOOS4) will be analyzed in intent-to-treat (ITT) and per-protocol (PP) 
analyses.  
The ITT population will be defined as those randomized to the two treatment arms. 
The PP population will be defined as those who participated in the MEDIC-treatment with at 
least 75% compliance with the exercise during the 12 week intervention period and stayed in the 
treatment arm allocated by randomization during the 1 year period. This means that the 
following will be excluded from the PP analysis: 
1)  Those who did not participate in all aspects of the MEDIC-treatment; 
2) Those participating in below 75% of the exercise sessions  
3) Those who were randomized to treatment according to the MEDIC-treatment alone but 
had an TKA during the 1 year period; and 
4) Those who were randomized to TKA + the MEDIC-treatment, but decided not to 
undergo surgery anyway 
Treatment effect will be determined as change in the primary outcome KOOS4 from baseline to 
the 1 year follow-up (see section 5.1.).  
The trial is designed as a superiority trial, i.e. we expect that the group allocated to TKA in 
addition to the MEDIC-treatment will improve at least 10 points more than the group allocated 
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to MEDIC-treatment in the primary outcome KOOS4 and the individual KOOS subscales from 
baseline to the primary endpoint after 1 year.  
The 1 year follow-up was chosen as the primary endpoint, since this is the time when the largest 
improvements are reported after TKA after which outcomes seems to decline 18. 
Since KOOS contains the full and original version of the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC), it has been suggested to apply a MIC of 10 points, 
which has been demonstrated for WOMAC19.  Recent studies in similar patient populations 16, 17 
have applied a MIC of 15%. However, percentage change from baseline is not recommended as 
an outcome in controlled trials, since it has low statistical power, is highly sensitive to changes 
in variance and fails to protect from bias in the case of baseline imbalance 20. We acknowledge 
that MIC is dependent on context factors such as population, intervention, and time to follow-
up21, which is why we will conduct an exploratory analysis applying a 15% difference in change 
in KOOS4 and the individual KOOS subscales between groups from baseline to the 1 year 
follow-up as the MIC.  
Based on the mentioned shortcoming with percent change as the outcome in controlled trials, we 
decided to maintain the 10 point MIC in KOOS4 and the individual KOOS subscales in this 
study. Therefore, the sample size calculation was based on 90% power to detect a 10 point 
difference between groups in KOOS4 after 1 year, which will be used to define the superiority 
margin (Δ=10points). 
Superiority will be tested using the two-sided 95% confidence interval (CI) of the mean change 
in KOOS4 between the two treatment groups. Treatment according to TKA + the MEDIC-
treatment will be considered superior to the MEDIC-treatment when the lower side of this 95% 
CI excludes the superiority margin (Δ). 
2.6.2. Secondary Endpoints 
Secondary endpoints will be analyzed for between group differences using ITT and PP analyses 
(see section 5.2.). 
Each subscale of the KOOS will be presented graphically for its development over the 1 year 
period.  
Each subscale of the KOOS, time (s) in Timed Up and Go, time (s) in 20-meter walk test, EQ-
5D Index, EQ VAS, weight (kg) and self-efficacy will be presented as mean (95% CI) for each 
treatment group, while usage of pain killers will be presented as actual numbers and proportions. 
Between group differences in change from baseline to 1 year will be statistically assessed. The 
analysis for weight will only be conducted for participants with BMI≥25. 
All issues during the trial found in the treatment records from the project physiotherapist, 
hospital records or the questionnaire from the follow-ups will be assessed to determine whether 
it represents an AE or not. AE will be presented in a table (see Table 1) and analyzed 
statistically by comparing actual numbers of serious AE (site other than index knee, index knee 
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and all serious events) and non-serious AE (site other than index knee, index knee and all 
serious events). Besides being analyzed according to ITT and PP, AE will be analyzed in an as 
treated analysis separating those undergoing TKA during the 1 year and those who did not. The 
two groups are defined using the following criteria: 
AE associated with TKA: 
1. Those receiving TKA by randomization 
2. All treatment dependent AE reported after TKA in those who had TKA even though 
randomized to the MEDIC-treatment alone throughout the follow up period 
AE associated with treatment according to a rehabilitation program alone: 
1. Those remaining in the ‘Rehabilitation alone’ group throughout the follow up period 
2. All treatment dependent AE reported prior to the TKA in those who had TKA even though 
randomized to the MEDIC-treatment alone 
3. Study Design 
3.1. Sample Size 
We used a common between-subject standard deviation of 14 to calculate the sample size 
needed to detect a 10 point difference in KOOS4 and the individual KOOS subscales (power of 
90 % and significance level at 0.05 (twosided)). The calculations showed that 41 participants 
were required in each group. 
To account for crossovers and missing data, the drop-out rate was set to 20 % and therefore, a 
total of 100 participants were randomized. 
3.2. Randomization and Blinding 
The schedule for randomization was randomly generated using a computer before the initiation 
of the trial. The randomization was by random permuted blocks, stratified according to the clinic 
(Frederikshavn or Farsoe) to control for variation in patient characteristics in the two clinics. To 
conceal the outcomes of the randomisation, the allocation numbers were put in concealed, 
opaque C5 envelopes. In blocks of eight, these envelopes were placed in consecutively 
numbered opaque larger envelopes (seven larger envelopes in total for each clinic). An 
independent staff member prepared the envelopes. These were kept in a locked location 
accessible only by one research assistant at each of the respective clinics. Following the 
informed consent and completion of the baseline measures, a smaller envelope from the 
numbered larger envelopes was opened by the research assistant and the allocation revealed to 
the participant. When only two smaller envelopes were left in the first of the numbered larger 
envelopes, the smaller envelopes of the second larger envelope were added. When there were 
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six smaller envelopes left in the sixth of the numbered larger envelopes at each clinic, the last 
two of the smaller envelopes were added. 
The outcome assessor is blinded to group allocation, is not involved in providing the 
interventions, and is unaffiliated with the treatment sites. The participants and the project 
physiotherapist delivering part of the interventions could not be blinded. The statistician 
performing the statistical analyses will be blinded to group allocation. 
The writing committee of this study (identical to the study chair in this SAP) will, prior to 
breaking the code, conduct two interpretations of the results on the basis of a blinded review of 
the data from the primary endpoint (changes from treatment A compared to changes from 
treatment B), one assuming that treatment A is TKA + the MEDIC-treatment, and the other 
assuming that treatment A is the MEDIC-treatment alone. Not until the writing committee has 
agreed that there will be no further changes in the interpretation the randomization code will 
broken, ensuring that bias in the interpretation is reduced. 
4. Study Population 
4.1. Subject Disposition 
Study procedures, including recruitment strategies and inclusion and exclusion criteria, have 
been published previously in a study protocol 6. Patient included in the trial were randomized to: 
A) TKA + the MEDIC-treatment (Medicine, neuromuscular Exercise, Diet (if needed), Insoles 
and Cognitive treatment (patient education)) or B) MEDIC-treatment alone. No patients 
fulfilling all eligibility criteria could be excluded.  
Patients fulfilling the eligibility criteria, but refusing to participate in the randomization, were 
offered to participate in an observational cohort, were they were able to choose which of the two 
treatment options they wanted. They followed the same intervention, follow-up schedule and 
study endpoints as patients in the randomized controlled trial, but were analyzed separately. 
Crossovers are a common problem in studies randomizing to surgical or non-surgical treatment 
22, 23. In this study participants who experienced impairment of their symptoms or lack of 
improvement during the 12week MEDIC-treatment were reassessed by the orthopaedic surgeon 
who assessed them in the recruitment phase. Pre-defined criteria for crossover to TKA or re-
surgery in TKA-patients are a score for QOL and/or for Pain equal to or below 25 on the KOOS 
and/or agreement between the participant and the orthopaedic surgeon that a TKA or re-surgery 
is necessary. This defined treatment failure in the study.  
The frequency of crossover to TKA, revision TKA and other surgeries will be registered and 
reported (Table 3). 
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5. Statistical Analysis 
5.1. Primary Endpoint 
The between-group difference in change in KOOS4 from baseline to 1 year follow-up will be the 
primary outcome, complemented by the individual KOOS subscales assessing pain, symptoms, 
ADL function and Quality of Life to allow for clinical in-depth interpretation. 
Between groups comparisons of treatment effect (change in KOOS4 from baseline to 1 year 
follow-up) will be dependent on data distribution. We expect the change to be normally 
distributed and analysis will be made using a mixed model ANOVA with subject being a 
random factor and visit (baseline, 3, 6 and 12 months), treatment arm (TKA + MEDIC, MEDIC) 
and site (Frederikshavn, Farsoe) being fixed factors. Baseline KOOS4 will be a covariate. 
Furthermore interactions between the fixed factors will be included in the model. P-values and 
95% CI will be presented to assess superiority. 
5.2. Secondary Endpoints 
Between groups comparisons of the change from baseline to the 1 year follow-up in all 
secondary endpoint will be handled similar to the primary endpoint.  
5.3. Major Protocol Deviations 
In the study protocol 6 we decided to apply a generalized estimating equations regression model 
(GEE) to analyse KOOS4 to take all follow-ups into account. However, since improvements in 
the two groups are not expected to follow the same pattern (It is expected that the TKA + 
MEDIC-treatment will have smaller improvement at the 3 months follow-up, but will have 
improved more at the 12 months follow-up compared to the MEDIC-treatment alone group) the 
GEE is not suitable for the analyses. The application of this method could potentially result in 
that between group differences at the 12 months follow-up were diminished due to differences 
in the opposite direction at the 3 or 6 months follow-up. Furthermore, the sample size 
calculation was based on the change from baseline to 12 months and not the change over several 
different follow-ups. After consulting with several statisticians, the authors decided to change 
the method of analyses for all endpoints to a mixed model ANOVA, which is the most suitable 
method to investigate changes from baseline to 12 months taking baseline values into account. A 
mixed model ANOVA is conditional (subject-specific opposite to a GEE that is population-
specific)24 and enables inclusion of the entire full analysis set (defined as an analysis set being as 
complete and as close to the ITT-principles of including all randomized patients as possible25) as 
even with an unbalanced dataset 26. Furthermore, the authors believe that the application of this 
method makes the results and the conclusion of the study easier to understand and interpret. 
Since this SAP is published before the 12 months follow-up is complete (February 2015) and 
any analyses have been performed, the change in method of statistical analyses will not induce 
any bias. 
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6. Implementation of Analysis Plan 
This SAP will be used as a work description for the statistician performing the analyses. All 
analyses will be performed by the same statistician and none of the investigators involved in this 
trial will perform any of the statistical analyses.  
The implementation of the SAP will be as follows: 
1. A ‘data collection form’ will be outlined in a collaboration between the database manager, 
statistician and principal investigator (Søren Thorgaard Skou). 
2. The database manager will code each treatment arm into ‘treatment A’ and ‘treatment B’ and 
thus leaving all others blinded from treatment during the analyses. 
3. Blinded data will be delivered to the statistician according to the ‘data collection form’. 
4. Primary, secondary and exploratory endpoint analyses will be made blinded from treatment 
5. Results will be presented to the writing committee of the trial (identical to the study chair in 
this SAP) where any uncertainties will be clarified and blinded interpretations of the primary 
endpoint results will be conducted prior to unblinding of data.  
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8. Tables 
8.1. Table 1. Adverse Events 
Adverse events MEDIC Usual Care P Value 
 Number of events  
Serious events    
Site other than index 
knee 
   
Musculoskeletal    
Skin    
Gastrointestinal    
Other    
Index knee    
Pain    
Swelling    
Subjective instability    
Decreased range of 
motion 
   
Distortion    
Other    
During surgery    
    Patella fracture    
    Tibia fracture    
    Femur fracture    
    Rupture of the 
patella tendon 
   
    Other    
Postoperatively    
   Arthrofibrosis    
   Deep infection    
   Surgery 
demanding skin 
necrosis 
   
   Surgery 
demanding scar 
tissue adherences 
   
   Thrombophlebitis 
in demand of 
anticoagulant 
treatment 
   
   Patella sub-
/luxation 
   
   Supra-condylar 
femur fracture 
   
   Permanent n. 
peroneus paresis 
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   Pulmonary 
embolism 
   
   Patella fracture    
   Aseptic loosening    
   Polyethylene 
defect (tibia) 
   
   Polyethylene 
defect (patella) 
   
   Secondary 
insertion of patella 
component 
   
   Instability    
   Pain without 
loosening 
   
  Other     
All serious events    
Nonserious events    
Sites other than 
index knee 
   
Index knee    
All nonserious 
events 
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8.2. Table 2. Baseline characteristics 
Baseline 
characteristics 
MEDIC Usual Care 
Women, n (%)   
Age (years), mean 
(SD) 
  
Weight (kg), mean 
(SD) 
  
Body Mass Index, 
mean (SD) 
  
OA in right knee, n 
(%) 
  
Duration of knee 
symptoms, n (%) 
  
     0-6 months   
     6-12 months   
     1-2 years   
     2-5 years   
     5-10 years   
    More than 10 
years 
  
Radiographic knee 
OA severity 
(Kellgren-
Lawrence), n (%) 
  
    Grade 2   
    Grade 3   
    Grade 4   
Charlson 
Comorbidity Index, 
median (iqr) 
  
Living alone, n (%)   
College education or 
equivalent, n (%) 
  
Employment status, 
n (%) 
  
    Working full-time 
or part-time 
  
    Sick leave   
    Pensioner   
Prior treatment of 
knee OA, n (%) 
  
    Exercise   
    Physiotherapy   
    Paracetamol   
    NSAIDs   
    Cortisone   
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injection 
    Surgery   
       Menisci with 
surgery 
  
       Knees with 
debridement 
  
       Knees with 
other surgery 
  
    Others   
KOOS scores   
    KOOS4   
    Pain   
    Symptoms   
    ADL   
    Sport/Rec   
    QOL   
EQ-5D, mean (SD)   
    EQ-5D Index   
    EQ VAS   
Functional 
performance, mean 
(SD) 
  
    Time (s) from the 
Timed Up and Go 
  
   Time (s) from the 
20-meter walk test 
  
Have used pain 
killers in the last 
week (n (%)) 
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8.3. Table 3. Treatment-related variables 
Variable MEDIC MEDIC + TKA P value 
Compliance with 
exercise during the 
12 weeks, n (%) 
   
Usage of the other 
aspects of the 
treatment program at 
least every day at the 
3month follow-up, n 
(%) 
   
    Insoles    
    Patient education    
    Dietary advice    
Surgery during 
follow-up 
   
    TKA   -------- --------- 
        Days from 
randomization, mean 
(SD) 
   
    Re-TKA    
       Days from 
randomization, mean 
(SD) 
   
    Brissement Forcé    
       Days from 
randomization, mean 
(SD) 
   
    Other surgery    
       Days from 
randomization, mean 
(SD) 
   
    Total number of 
surgery 
   
Satisfied with the 
treatment effects 
after 12months 
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8.4. Table 4. Outcome at 1 year 
Baseline 
characteristics 
Improvement in 
MEDIC-group  
Improvement in MEDIC 
+ TKA-group  
Between-group 
difference 
Mean (months) 
follow-up after start 
of MEDIC-treatment 
(95% CI) 
   
Primary endpoint: 
mean change in 
KOOS4 from 
baseline to 1 yr 
(95% CI) 
   
Secondary Endpoints    
    Mean change in 
KOOS subscales 
score (95% CI) 
   
       Pain    
       Symptoms    
       ADL    
       Sport/Rec    
       QOL    
Mean change in time 
(s) from the Timed 
Up and Go (95% CI) 
   
    Mean change in 
time (s) from the 20-
meter walk test (95% 
CI) 
   
    Mean change in 
EQ-5D (95% CI) 
   
       EQ-5D Index    
       EQ VAS    
    Mean weight 
change (kg; 95% CI) 
   
Change in 
participants using 
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pain killers in the 
last week (n (%)) 
 
